In the news:
Novo Nordisk Launches Wegovy Weight-Loss Drug in China - Novo Nordisk sells hit weight-loss drug in China--at fraction of US price - Novo Nordisk Launches Wegovy in China With Prices Well Below US - Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says - Americans seeking Eli Lilly and Novo Nordisk's weight-loss drugs turn to compounded market - Novo Nordisk's obesity-fighting drugs fatten Denmark's economy - With Novo Nordisk success, is there a "Nokia risk" for Denmark? - With Novo Nordisk success, is there a "Nokia risk" for Denmark? - Ozempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs - Novo Nordisk's weight loss drug Wegovy available in France from Tuesday
Novo Nordisk
Save
ShareKey facts
- city: Bagsvaerd
- country: Denmark
- sector: Health Care
- foundation year: 1923
- industry: Biotechnology
- CEO: Lars Fruergaard Jorgensen
Classified as: organization
Summary
Novo Nordisk is a company. It is located in Bagsvaerd, Denmark and was founded in 1923. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Business
Novo Nordisk is one of the companies in Denmark, companies in Biotechnology, companies in Health Care and 3,466,499 companies in our database.
- Assets: 26.2B $
- Debt: 3.4B $
- Employees: 49,295 people
- Free cash flow: 7.3B $
- Market cap: 239.6B $
- Profits: 6.4B $
- Revenues: 20.1B $
Stocks from Novo Nordisk
Explore more on business
Talking Points:
- Novo Nordisk | driving change to defeat serious chronic diseases
- Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
- Daily news about diabetes, obesity and other serious chronic diseases. We're global, but here in person for your questions and comments 💬 Community guide 👇
- Driving change to defeat diabetes and other serious chronic diseases. Join us to learn more about our latest innovations | Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and ...
- Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Learn more about talking points